Pharmacokinetics of meropenem in patients with liver disease

Clinical Infectious Diseases

Volumn 24, Issue SUPPL. 2, 1997, Pages

  Thyrum, Per T ^a   Yeh, Chiao ^b   Birmingham, Bruce ^b   Lasseter, Kenneth ^b  

^a Zeneca Pharmaceutical   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; ICI 213689; MEROPENEM; UNCLASSIFIED DRUG;

ALCOHOL LIVER CIRRHOSIS; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BACKACHE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; INJECTION PAIN; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; PHARMACOKINETICS; PRIORITY JOURNAL; STEADY STATE;

EID: 0030999058     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/24.supplement_2.s184     Document Type: Article

References (14)

1. Bax RP, Bastain W, Featherstone A, Wilkinson DM, Hutchison M, Haworth SJ. The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother 1989;24(suppl A):311-20.
2. Burman L̊, Nilsson-Ehle I, Hutchison M, Haworth SJ, Norrby SR. Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem. J Antimicrob Chemother 1991;27:219-24.
3. Harrison MP, Moss SR, Featherstone A, Fowkes AG, Sanders AM, Case DE. The disposition and metabolism of meropenem in laboratory animals and man. J Antimicrob Chemother 1989;24(suppl A):265-77.
4. Nilsson-Ehle I, Hutchison M, Haworth SJ, Norrby SR. Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males. Eur J Clin Microbiol Infect Dis 1991;10:85-8.
5. Drusano GL, Hutchison M. The pharmacokinetics of meropenem. Scand J Infect Dis Suppl 1995;96:11-6.
6. Wise R, Logan M, Cooper M, Ashby JP, Andrews JM. Meropenem pharmacokinetics and penetration into an inflammatory exudate. Antimicrob Agents Chemother 1990;34:1515-7.
7. Mouton JW, Michel MF. Pharmacokinetics of meropenem in serum and suction blister fluid during continuous and intermittent infusion. J Antimicrob Chemother 1991;28:911-8.
8. Bedikian A, Okamoto MP, Nakahiro RK, et al. Pharmacokinetics of meropenem in patients with intra-abdominal infections. Antimicrob Agents Chemother 1994;38:151-4.
9. Harrison MP, Haworth SJ, Moss SR, Wilkinson DM, Featherstone A. The disposition and metabolic fate of 14C-meropenem in man. Xenobiotica 1993;23:1311-23.
10. Ljungberg B, Nilsson-Ehle I. Pharmacokinetics of meropenem and its metabolite in young and elderly healthy men. Antimicrob Agents Chemother 1992;36:1437-40.
11. Leroy A, Fillastre JP, Borsa-Lebas F, Etienne I, Humbert G. Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment. Antimicrob Agents Chemother 1992;36:2794-8.
12. Leroy A, Fillastre JP, Etienne I, Borsa-Lebás F, Humbert G. Pharmacokinetics of meropenem in subjects with renal insufficiency. Eur J Clin Pharmacol 1992;42:535-8.
13. Chimata M, Nagase M, Suzuki Y, Shimomura M, Kakuta S. Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease. Antimicrob Agents Chemother 1993:37:229-33.
14. St. Peter JV, Awni WM. Quantifying hepatic function in the presence of liver disease with phenazone (antipyrine) and its metabolites. Clin Pharmacokinet 1991;20:50-65.